SCHEMBL25742017

SCHEMBL25742017

Cn1cc(C(=O)C(N)CO)c2ccc(Cl)cc21

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
LMNA P02545 2/20 0.39
MITF O75030 1/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPT P10636 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
PTGER1 P34995 1/20 0.39
KDM4E B2RXH2 1/20 0.39
CDK2 P24941 1/20 0.38
KMO O15229 2/20 0.37
UTS2R Q9UKP6 1/20 0.36
MAOB P27338 1/20 0.36
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
CYP2C9 P11712 1/20 0.35
MAT2A P31153 1/20 0.35
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
NR4A2 P43354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25742037 0.90 KDM4E (0.46) KMT2ALMNAMITFALDH1A1MAPT
SCHEMBL26261191 0.85 HAT1 (0.43) LMNAALDH1A1PTGER1KMOCNR1
SCHEMBL25742001 0.84 IDO1 (0.47) KMT2ALMNAMITFALDH1A1MAPT
SCHEMBL25742019 0.82 PTGER1 (0.40) KMT2ALMNAMITFALDH1A1MAPT
SCHEMBL25742021 0.80 CDK2 (0.38) KMT2ALMNAMITFALDH1A1MAPT
SCHEMBL6592243 0.78 MAPT (0.51) KMT2ALMNAMITFALDH1A1MAPT
SCHEMBL25742054 0.77 PTGER1 (0.42) KMT2ALMNAMITFALDH1A1MAPT
SCHEMBL10258241 0.77 KMT2A (0.52) KMT2ALMNAMITFALDH1A1MAPT
SCHEMBL22450703 0.77 KCNH2 (0.49) KMT2ALMNAMITFALDH1A1MAPT
SCHEMBL26261215 0.77 HAT1 (0.45) KMT2ALMNAALDH1A1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-08-17 US disclosed
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT TACTOGEN INC (US) 2023-08-17 US disclosed
WO-2023107715-A1 SPECIALIZED COMBINATIONS FOR MENTAL DISORDERS OR MENTAL ENHANCEMENT TACTOGEN INC (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257347-A1 ADVANTAGEOUS TRYPTAMINE COMPOSITIONS FOR MENTAL DISORDERS OR ENHANCEMENT HTR6, TPH2, TPH1 KMT2A 1439/4885LMNA 3734/4885MITF 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.